Although the impact of this HP polymorphism on cardiovascular disease, including risk stratification (Levy et al., 2002), has been investigated in various studies, the results have been controversial and most of the studies were conducted in non‐Chinese population (De Bacquer et al., 2001; Levy et al., 2002; Simpson et al., 2011; Suleiman et al., 2005). The gene discussed is HP; the disease is cardiovascular disorder.